Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Pareto Healthcare Conference 2020
20 slides from Arcticzymes Technologies Asa's conference presentation, Sep 2, 2020
Slide 1: ArcticZymes Technologies: Shaped by the Arctic
ArcticZymes Technologies Shaped by the Arctic Jethro Holter, CEO 2nd September 2020
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking in
Slide 3: Agenda
Agenda 1 Business Model 2 Markets & Customers 3 Business Structure 4 Financials 5 Growth Strategy 6 Summary
Slide 4: Business Model
Business Model
Slide 5: Specialist supplier of best-in-class novel enzymes
Specialist supplier of best-in-class novel enzymes Restructured Senior board and Financially B2B and OEM business new CEO strong sales Focus on profitability and Experienced leadership Core business profitable Broad customer base and accelerated growth and commercial team and growing rapidly long-te
Slide 6: Our Novel Enzyme Products
Our Novel Enzyme Products Different ways in which enzyme can manipulate DNA, for example: Salt Active IsoPolTM Ligase Proteinase Nuclease Polymerase Cuts up and destroys DNA Amplifies/Copies DNA Joins DNA together Digests cells to release DNA 6
Slide 7: Markets & customers
Markets & customers
Slide 8: Target Markets & Customers
Target Markets & Customers Size and growth potential 40 Therapeutics 30 Gene therapy & DNA vaccine manufacturers CAGR (%) Molecular Research 20 Research kit manufacturers Molecular Diagnostics Commercial diagnostic test developers 10 0 0 1 2 3 4 5 6 7 8 9 10 Market size Billion USD 8 [Source: intern
Slide 9: Business Value Proposition
Business Value Proposition A reliable supplier our commercial partners trust Partnership approach Driving long-term relationships, putting our customers' needs at the center of what we do Security of supply Timely, reliable and uninterrupted supply Unique enzyme Unique origins features Direct access
Slide 10: Business Structure
Business Structure
Slide 11: Business Structure
Business Structure Biotec BetaGlucan AS Non-core business ArcticZymes AS Markets immunomodulating beta-glucan products, serving several market areas Core business Develops, manufactures and commercializes novel enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics 11
Slide 12: ArcticZymes: Profitable & fast growing
ArcticZymes Profitable & fast growing EBITDA positive since 2015 Achieved annual sales growth 23% CAGR (2015-2019) Addressing three growth market segments: Molecular research: consistent growth, addressing DNA sequencing, gene synthesis & PCR applications Molecular diagnostics: growing, additional u
Slide 13: Biotec BetaGlucans
Biotec BetaGlucans Cash generative Immune-modulating beta-glucans products derived from yeast cell walls Segments M-Gard® consumer & M-Glucan® animal health Cash generative, albeit reliant on few, large customers First half uplift in sales in consumer health as a result of Covid-19 and demand to imp
Slide 14: Financials
Financials
Slide 15: Q2 Financial Highlights
Q2 Financial Highlights Best quarterly performance to date 50,000 Sales, Gross Profit & EBITDA Sales 40,000 Gross profit Q2 sales up 163% NOK 44.3 m (2019: NOK 16.9m) EBITDA 30,000 EBITDA of NOK 27.2 m (2019: NOK -0.5m) 20,000 Cash at period end: NOK 56.2 m (2019: NOK 21.4m) 10,000 EPS of NOK 0.53 (
Slide 16: Growth Strategy
Growth Strategy
Slide 17: Growth Strategy
Growth Strategy European’s leading one-stop-shop enzyme supplier Simplified Workflow Sanger Proteinase Reverse Transcriptases, Cod UNG, rSAP, Sequencing Polymerases Ligases, etc.. Next Generation Sequencing (NGS) Real time PCR/LAMP Cells DNA Amplified DNA Detection and Analysis Achieved through buil
Slide 18: Summary
Summary
Slide 19: Summary
Summary High Growth Accelerate Build Long-Term Business Expansion Shareholder Value About leverage existing Broaden product range: Driven by sustainable and new long-term B2B • Bolt and build via M&A profitablity and topline relationships • Ramp up innovation growth pipeline & operations 19
Slide 20: Thank you
A ArcticZymes Technologies
ArcticZymes Technologies — Pareto Healthcare Conference 2020 on 6ix